Your browser is no longer supported. Please, upgrade your browser.
180 Life Sciences Corp.
Index- P/E- EPS (ttm)-1.97 Insider Own17.50% Shs Outstand24.13M Perf Week-8.99%
Market Cap246.85M Forward P/E- EPS next Y- Insider Trans-1.04% Shs Float13.80M Perf Month27.24%
Income-9.30M PEG- EPS next Q- Inst Own7.30% Short Float15.81% Perf Quarter62.64%
Sales- P/S- EPS this Y-130.90% Inst Trans12.74% Short Ratio0.90 Perf Half Y310.84%
Book/sh0.91 P/B11.24 EPS next Y- ROA-76.60% Target Price- Perf Year-3.13%
Cash/sh0.02 P/C493.70 EPS next 5Y- ROE-156.80% 52W Range1.90 - 13.05 Perf YTD274.73%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-21.58% Beta-0.50
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low438.42% ATR0.78
Employees2 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)57.76 Volatility7.47% 7.81%
OptionableYes Debt/Eq0.55 EPS Q/Q- Profit Margin- Rel Volume0.10 Prev Close10.15
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.42M Price10.23
Recom- SMA2013.73% SMA5013.14% SMA20048.53% Volume251,484 Change0.79%
Jun-10-21 09:12AM  
Jun-01-21 08:00AM  
May-28-21 08:00AM  
May-21-21 04:45PM  
Apr-20-21 08:00AM  
Apr-19-21 05:00PM  
Apr-14-21 08:15AM  
Mar-26-21 08:30AM  
Mar-25-21 08:30AM  
Mar-24-21 08:30AM  
Mar-08-21 01:30PM  
Feb-24-21 04:00PM  
Feb-19-21 09:00AM  
Feb-17-21 12:00AM  
Jan-11-21 08:00AM  
Jan-05-21 02:50PM  
Dec-03-20 11:08AM  
Nov-24-20 10:00AM  
Nov-23-20 08:30AM  
Nov-17-20 08:00AM  
Nov-10-20 11:46AM  
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KRAUSS MARLENE10% OwnerDec 17Sale2.4816,50640,8802,006,858Dec 17 05:29 PM
KRAUSS MARLENE10% OwnerDec 15Sale2.4017,87742,9052,543,676Dec 17 05:29 PM
KRAUSS MARLENE10% OwnerDec 14Sale2.4510,00024,5002,561,553Dec 17 05:29 PM
KRAUSS MARLENE10% OwnerNov 25Sale2.7812,18233,8092,571,556Dec 01 07:00 PM
KRAUSS MARLENE10% OwnerNov 23Sale3.2660,633197,6762,583,738Dec 01 07:00 PM
KRAUSS MARLENE10% OwnerNov 19Sale2.1233,44570,8372,644,371Dec 01 07:00 PM
KRAUSS MARLENE10% OwnerNov 18Sale2.316,70015,4802,677,816Dec 01 07:00 PM
KRAUSS MARLENE10% OwnerNov 17Sale2.263,3007,4452,684,516Dec 01 07:00 PM